<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Available insulins&lt;sup&gt;[1]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Available insulins<sup>[1]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Available insulins<sup>[1]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="3" width="10%"></colgroup><colgroup width="50%"></colgroup> <tbody> <tr> <td class="subtitle1">Type</td> <td class="subtitle1">Onset (hours)</td> <td class="subtitle1">Peak (hours)</td> <td class="subtitle1">Duration (hours)</td> <td class="subtitle1">Comments</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Ultra-rapid-acting</td> </tr> <tr> <td class="indent1"> <p>Faster aspart</p> Insulin lispro-aabc</td> <td>0.1 to 0.2</td> <td>1 to 3</td> <td>3 to 5</td> <td>Duration of action may be shorter.</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Rapid-acting</td> </tr> <tr> <td class="indent1">Lispro*/aspart*/glulisine</td> <td>0.15 to 0.35</td> <td>1 to 3</td> <td>3 to 5</td> <td> </td> </tr> <tr> <td class="subtitle2_left" colspan="5">Short-acting</td> </tr> <tr> <td class="indent1">Regular</td> <td>0.5 to 1</td> <td>2 to 4</td> <td>5 to 8</td> <td>Longer duration of action if larger dose.</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Intermediate-acting</td> </tr> <tr> <td class="indent1">NPH</td> <td>2 to 4</td> <td>4 to 12</td> <td>12 to 24</td> <td>Peak and duration quite variable.</td> </tr> <tr> <td class="indent1">NPL</td> <td>Approximately 2</td> <td>6</td> <td>15</td> <td>Activity profile similar to NPH; can be mixed with insulin lispro. Not available in the United States.</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Basal long-acting</td> </tr> <tr> <td class="indent1">Glargine*</td> <td>2 to 4</td> <td>8 to 12 (not pronounced)</td> <td>22 to 24</td> <td> <p>Half-life is shorter in some patients, requiring division of the daily dose into 2 injections per day.</p> Cannot be mixed with other insulins, because this alters pharmacokinetics.</td> </tr> <tr> <td class="indent1">Detemir</td> <td>1 to 2</td> <td>4 to 7 (not pronounced)</td> <td>20 to 24</td> <td> <p>Duration of action is dose dependent. At higher doses (≥0.8 units/kg), mean duration of action is longer and less variable (22 to 23 hours). At lower doses, mean duration of action is shorter and twice-daily injections are often needed.</p> Cannot be mixed with other insulins, because this alters pharmacokinetics.</td> </tr> <tr> <td class="indent1">Glargine U300</td> <td>2 to 6</td> <td>None</td> <td>30 to 36</td> <td>Cannot be mixed with other insulins, because this alters pharmacokinetics.</td> </tr> <tr> <td class="indent1">Degludec</td> <td>0.5 to 1.5</td> <td>None</td> <td>&gt;42</td> <td> <p>Less day-to-day variation in glucose-lowering effect at steady state (after 2 to 3 days' use) relative to glargine U100 and detemir.</p> Can be mixed with insulin aspart; coformulation with aspart available in some countries.</td> </tr> </tbody></table></div><div class="graphic_lgnd">The numbers indicated above are approximations and are influenced by many factors including (but not limited to) presence and type of antibodies to the specific insulin, site of injection, and mass action effect. Premixed insulins are not generally recommended but are sometimes useful to reduce the number of injections in selected patients; mixes consist of NPH and regular (70:30 mix) or NPH and Lispro (75:25 mix), as well as other concentrations. Other new insulins are presently in clinical trials. No inhaled insulin preparation is currently available, but both orally absorbed and inhaled insulin preparations are being developed.</div><div class="graphic_footnotes"><p>NPH: neutral protamine hagedorn; NPL: neutral protamine lispro.</p>
    
    * Certain biosimilar insulins for lispro, aspart, and glargine are approved for children in some countries, including the United States, Canada, and Europe. The US Food and Drug Administration uses the term "similar" rather than "biosimilar" for technical reasons<sup>[2]</sup>.</div><div class="graphic_reference">References:
    <ol>
<li>Cengiz E, Danne T, Ahmad T, et al. ISPAD
        Clinical Practice Consensus Guidelines 2022: Insulin treatment in children and
        adolescents with diabetes. Pediatr Diabetes 2022; 23:1277.</li>
<li>
        In brief: Another insulin lispro (Admelog) for
        diabetes. Med Lett Drugs Ther 2018; 60:e109.</li>
</ol></div><div id="graphicVersion">Graphic 61880 Version 12.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
